Real-Time Imaging for Particle Therapy in Cancer Treatment 

A precision approach to real-time dosage verification in proton therapy.

Background 

Proton therapy is an advanced radiation treatment known for its precision in targeting tumors while sparing healthy tissue. However, current systems lack real-time verification, leading to uncertainties in dose delivery and reduced treatment accuracy. The NOVO technology addresses these challenges by introducing innovative imaging capabilities that enhance treatment precision and patient outcomes. 

 

Advantages 

  • Real-Time Dose Tracking: Enables precise dose verification during therapy. 

  • Increased Safety: Reduces radiation exposure to healthy tissues, minimizing side effects. 

  • Cost-Effective Add-On: Envisioned to integrate seamlessly with existing proton therapy setups. 

 

Technology Description 

At the heart of this solution is the NOVO Compact Detector Array (NOVCoDA), which uses scintillator bars to detect neutrons and gamma photons in real time. This capability ensures accurate dose monitoring and treatment adaptation. This cutting-edge system has shown promising results in lab testing and is currently at technology readiness level (TRL) 3. 

 

Business Opportunity 

We are seeking partnerships and collaboration with industry partners and potential licensees to advance the development and bring a clinical solution to market. 

 

Protection 

  • Patents and patent applications: CN113660979A; EP3952986A1; EP3952986A4; JP2022528967A; JP7555351B2; NO20190493A1; NO20200434A1; NO346536B1; US12036427B2; US2022161061A1; WO2020209730A1 

 

Inventors 

  • Ilker Meric, Western Norway University of Applied Sciences 

  • Kristian Smeland Ytre-Hauge, University of Bergen 

 

Contact 

For inquiries or licensing opportunities, please contact: 

Daniel Haischer 
Senior Innovation Manager 
daha@visinnovasjon.no 
+47 905 21 453 

 

Media Attention 

Forrige
Forrige

NAD+ Therapy for Parkinson’s: A Novel Approach

Neste
Neste

Novel Radiosensitizers for Radioresistant Tumors